















































      Testicular tumors are rare in children. They account for only 1% 
of all pediatric solid tumors and 3% of all testicular tumors[1,2]. The 
annual incidence of testicular tumors in children is estimated to be 
between 1.6 and 2 per 100,000 children[3-5]. Testicular germ cell 
tumors are the most common testicular malignancy in children[6]. 
The modern standard comprehensive treatment is surgery combined 
with chemotherapy, yielding a 5-year overall survival (OS) rate of 
75%–100% for children with testicular malignant germ cell tumors 
(MGCT)[7-9]. A study by the Pediatric Oncology Group/Children’s 
Cancer Group (POG/CCG) demonstrated that the 6-year event-free 
survival (EFS) and OS rates for children with stage I testicular germ 
cell tumors who underwent orchiectomy were 78.5% and 100%, 
respectively[10], whereas the 6-year EFS and OS rates for children 
with stage II testicular germ cell tumors who received orchiectomy 
and chemotherapy were both 100%[7]. Data from clinical studies 




excellent survival rates when treated with surgery alone[7,10], whereas 
the expert consensus is that children with stage II to IV germ cell 
tumors require adjuvant chemotherapy after surgery[9]. Indeed, for 
patients with stage II germ cell tumors, further intervention following 
surgery is needed when serum tumor markers increase or fail to 
normalize after an appropriate period of half-life time has elapsed. 
Despite having no evidence of residual disease by either imaging 
or pathologic examination, these patients are good candidates for 
adjuvant chemotherapy. Fearing toxicity, however, many parents 
decided that their children should forgo adjuvant chemotherapy. 
Few studies have evaluated the prognosis, disease recurrence, and 
survival rate of children with stage II testicular MGCT treated with 
surgery alone. To fill this gap, we studied the medical records of 
24 children with stage II MGCT and retrospectively analyzed their 
relapse and OS rates.
1BUJFOUTBOE.FUIPET
1BUJFOUT
      We reviewed the medical records of 24 children who were treated 
for stage II testicular MGCT at the Sun Yat-sen University Cancer 








abdominal/pelvic computed tomography (CT) scan, color Doppler 









lactate dehydrogenase. All patients underwent standard surgical 
treatment, which consisted of orchiectomy with high ligation of the 























those treated with orchiectomy via transscrotal surgery; microscopic 
disease in the scrotum or high in the spermatic cord (<5 cm from the 
proximal end); and retroperitoneal lymph node involvement (<2 cm) 
and/or increased tumor marker levels after an appropriate period 
of time. For this study, children with stage II disease whose serum 
tumor markers increased or failed to normalize after an appropriate 
period of half-life time post-orchiectomy and who had no evidence of 
















composed of cisplatin 20 mg/m2 intravenous drip each day on days 
1–5, etoposide 100 mg/m2 intravenous drip each day on days 1–5, 
and bleomycin 15 mg/m2 intramuscular on day 1. Treatment was 
repeated at 21-day intervals for a total of 4 cycles.
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      The primary follow-up data included physical examination, 
determination of tumor markers, chest radiograph, CT scan or color 



























year, and annually thereafter. Physical examination, chest radiograph, 
CT scan or color Doppler ultrasound of the abdomen and pelvis, and 
color Doppler ultrasound of the bilateral testes and epididymis were 
performed every 3 months in the first year, every 6 months in the 
second year, and once a year thereafter.
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      Recurrence was defined according to any of the following 
criteria: (1) tumor marker levels increased post-surgery after initial 
































occurrence of progressive disease (PD), relapse, second malignancy, 


















      SPSS 16.0 statistical software was used. Survival estimates 
were computed and compared using the Kaplan-Meier method and 
























serum tumor markers increased or failed to normalize after an 
appropriate period of half-life time post-surgery. Twenty-one patients 
were treated with surgery alone, and 3 patients were treated with 
surgery and adjuvant chemotherapy. Patient characteristics are 
shown in Table 1. The median age was 24 months (range, 4 months 
to 17 years). A total of 20 tumors (83.3%) had yolk sac (endodermal 
sinus) histology, whereas the histology of the remaining 4 included 
seminoma, embryonal carcinoma, teratoma with malignant epithelial 
component, and mixed germ cell tumor (yolk sac tumor and 
embryonal carcinoma). AFP levels were elevated in all patients with 




























      No relapse or metastasis was observed in the 3 patients who 
received adjuvant chemotherapy. Of the 21 patients who were treated 
with surgery alone, 16 (76.2%) had a relapse and/or metastasis; all 
16 patients showed elevated AFP levels, and 15 patients showed 
relapse on images (CT for 14 cases and color Doppler ultrasound 
for 1 case). Patient characteristics are shown in Table 2. The median 
time from surgery to relapse was 4 months (range, 0.5 to 14.3 
months). The relapses occurred locally in 1 patient and regionally 
(retroperitoneal lymph nodes) in 2 patients. Ten patients (62.5%) 
subsequently showed evidence of distant metastasis. Two patients 
had local relapse and distant metastasis. The AFP level was over 
10,000 ng/mL in 11 patients. In 9 patients, AFP levels failed to 


















chemotherapy. The 16 children who experienced relapse and 
metastasis underwent the following treatments (Table 2): salvage 
chemotherapy (11 patients), second-look surgery and salvage 
chemotherapy (2 patients), salvage chemotherapy followed by 
second-look surgery (2 patients), and 1 cycle of salvage chemo-
therapy followed by second-look surgery and further salvage 
chemotherapy (1 patient). The parents of 1 patient refused further 
treatment after 1 cycle of chemotherapy; the remaining 15 patients 
had normalized AFP values after salvage treatment and achieved 
complete response. The patients received a median of 6 cycles 
(range, 1 to 10 cycles) of salvage chemotherapy. There were a total 
of 2 deaths. The patient whose treatment was stopped died due to the 
tumor 3 months later. The other patient achieved complete response 
after salvage treatment but developed lung and pelvic metastases 
7 months later and died of the tumor after stopping treatment. The 
remaining 14 patients were alive at the time of last follow-up.
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chemotherapy. The total number of chemotherapy cycles for all 16 
patients who relapsed was 78. The main adverse effect was bone 
marrow suppression. The rates of grade IV bone marrow suppression 
















































were 0% and 7.7%, respectively, and the rates of grades III 
gastrointestinal reaction were 2.6% and 61.5%, respectively. Renal 
toxicity, ototoxicity, and lung toxicity were not observed. No patients 
died of adverse effects. No second malignancies occurred.
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      The median follow-up period was 37.9 months (range, 6 to 109 
months). The 3-year EFS and OS rates of all 24 patients were 33.3% 
and 91.7%, respectively. The 3-year EFS rates of patients who were 
treated with surgery alone and surgery combined with adjuvant 
chemotherapy were 23.8% and 100%, respectively (P = 0.042; 
Figure 1). The 3-year OS rates of patients who were treated with 
surgery alone and surgery combined with adjuvant chemotherapy 
were 90.5% and 100%, respectively (P = 0.588; Figure 2). EFS 
rate was higher for patients with AFP levels İ 400 ng/mL when 












different for patients with AFP levels <10,000 ng/mL as compared 
with those with AFP levels ı 10,000 ng/mL (41.7% vs. 18.2%, P = 
0.061). In the 21 patients who were treated initially with surgery and 
observation (watch-and-wait approach), EFS rate was greater for 
patients in whom the AFP level normalized 1 month after orchiectomy 
as compared with patients whose AFP level failed to normalize (75.0% 
vs. 11.8%, P = 0.044). 
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      Patients with stage II germ cell tumors of the testes have high 
survival rates when treated with surgery and adjuvant chemotherapy; 
the OS rates in several studies have been over 95%[4,7,9,11-13]. In a 












6-year EFS and OS rates were 100%[7]. In an earlier United Kingdom 
Children’s Cancer Study Group (UKCCSG) study, children with 





[13]. Another UKCCSG study 
demonstrated that the 5-year EFS and OS rates of children with 























bleomycin) chemotherapy, and the 5-year OS rate was 95%[11]. A 




























before the age of 2 years. Adjuvant chemotherapy is routinely 
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recommended for these young patients with stage II disease whose 
serum tumor markers fail to normalize after an appropriate period 
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chemotherapy for these patients. Indeed, in the present study, the 
parents of 21 patients refused adjuvant chemotherapy. The relapse 
rate was high at 76.2%. Although there was no imaging or pathologic 













of time indicated the presence of residual tumor cells that secrete 
these marker proteins[10,15]. The 3 patients in the present study who 
received orchiectomy and adjuvant chemotherapy had a 3-year EFS 
rate of 100%. Thus, children with stage II disease with tumor markers 
that failed to normalize need to receive adjuvant chemotherapy 
to eliminate residual tumor cells, and thereby reduce recurrence 
and improve survival. At the time this protocol was designed, 
tumor marker decline during chemotherapy had demonstrated in a 

















Thus, for an AFP level of 400 ng/mL after surgery, the level should 
fall below 25 ng/mL at 28 days after surgery. We suggest that post-
surgery, AFP should be monitored weekly until it reaches normal 
levels, which refers to a measurement less than 25 ng/mL. If serum 
tumor markers fail to normalize after an appropriate period of time, 
the patient should be treated with chemotherapy. 
      The level of AFP at diagnosis is closely related to prognosis. Two 
studies revealed that patients with an AFP level ı 10,000 ng/mL had 
a poor prognosis[17,18]. In the present study, 12 patients had AFP levels 
>10,000 ng/mL. We compared the 3-year EFS rates between patients 











0.061). This may be due to the limited number of cases in this study. 
In contrast, the 3-year EFS rate for the 21 children who underwent 
surgery alone was higher when the time to AFP normalization was 
<1 month compared with ı 1 month (75.0% vs. 11.8%, P = 0.044). 
The rate of AFP decline to normalization was therefore associated 
with prognosis. If the AFP level does not decline to normal 1 month 
after surgery, the patient should receive adjuvant chemotherapy. 
Nevertheless, AFP levels in most patients do not decline to normal, 
probably due to residual tumor cells, though potentially due to liver 



























suggest that patients who exhibit these characteristics should be 



















chemotherapy and chemotherapy after relapse. Children who 
were treated with orchiectomy followed by 4 cycles of adjuvant 
chemotherapy had an excellent outcome. The 3-year OS rate of 
children with relapse and metastasis remained high (90%) after 
salvage treatment. Patients in this group received more cycles of 
chemotherapy. In this study, the median number of cycles after 
relapse was 6, and the maximum number was 10. The main adverse 
reaction observed in this study was bone marrow suppression. 
The rates of grade IV bone marrow suppression for initial adjuvant 
chemotherapy and chemotherapy after relapse were 0% and 7.7%, 
respectively, and the rates of grades III gastrointestinal reaction 
were 2.6% and 61.5%, respectively. Toxicity became more severe as 
the number of chemotherapy cycles after relapse increased. Renal 
toxicity, ototoxicity, and lung toxicity were not observed. A study 
from UKCCSG showed that the rates of renal toxicity and ototoxicity 
were 45% and 10%, respectively, and 1 patient died of secondary 
leukaemia[13]. Therefore, there is a relatively high level of toxicity after 
recurrence, even with a high survival rate. 
      Most cases of recurrence are detected using tumor markers or 
abdominal CT scan[20, 21]. In this study, recurrence was detected by 
using CT scan in 87.5% (14 of 16) patients. Furthermore, a report 
showed that 80% of events occurred in the first year post-surgery, 
and more than 90% of events occurred during the first 2 years[22]. 


























subsequent years[23, 24]. In this study, the median time from surgery 
to relapse was 4 months (range, 0.5 to 14.3 months). Consequently, 
close follow-up is essential for patients in the first 5 years. Tumor 
markers should be monitored, and abdominal CT scan should be 
obtained periodically.
      Patients with recurrent disease can still achieve long-term 
survival with salvage therapy. Of the 16 children who experienced 
relapse and metastasis in this study, 11 underwent salvage 
chemotherapy, 2 underwent second-look surgery and salvage 
chemotherapy, 2 received salvage chemotherapy first and then 
underwent second-look surgery, and 1 received 1 cycle of salvage 
chemotherapy followed by second-look surgery and additional 
salvage chemotherapy. Except for 1 patient who stopped treatment 
after 1 cycle of chemotherapy, the remaining 15 patients had 
normalized AFP levels following salvage treatment and achieved CR. 
Fourteen patients were alive after salvage treatment. In the case of 
stage I disease, all patients with relapse or progression appeared 
to be cured with further surgical excision and chemotherapy[9,10]. 
Few studies have evaluated the survival rate of children with stage 
II MGCT treated with surgery alone. One report of patients with yolk 
sac tumors showed AFP normalization in 72%, persistent elevation 
in 8%, and relapse in 16% of patients who experienced transient 
lowering after radical orchiectomy[25]. All 6 patients who showed 
either elevation or relapse of AFP received salvage chemotherapy. 
This therapy rescued all but 1 patient, who was further treated with 
peripheral blood stem cell transplantation. None of the patients 
experienced relapse after these treatments. Thus, patients who 
experience relapse still have a high chance of survival with salvage 
therapy




children with stage II MGCT, adjuvant chemotherapy should be given 
to those whose serum tumor markers increase or fail to normalize 
after an appropriate period of half-life time following surgery even if 
there is no imaging or pathologic evidence of residual disease. Tumor 
markers should be monitored periodically post-surgery. If serum 
tumor markers fail to normalize after an appropriate period of half-
life time, the patient should be treated with chemotherapy as soon as 
possible.
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